Radar on Specialty Pharmacy

Sandoz Launches First Interchangeable Denosumab Biosimilars at Discounted WACs

  • Jun 12
    Popup Image

    Jun 12, 2025

    The first biosimilars of Amgen Inc.’s Prolia (denosumab) and Xgeva (denosumab) have launched onto the U.S. market, with more expected to follow soon. On June 2, Sandoz said that it had launched Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz), with an eye on bringing a more cost-effective option to patients of the reference drugs, which have undergone more than 20 price increases since their approval. It remains to be seen whether the manufacturer will choose the private-label route favored by recent biosimilar launches.

    Approved on March 5, 2024, the agents also are the only biosimilars of Prolia and Xgeva, respectively, with interchangeable status for all indications of the reference drugs.

    Read more
      • Radar on Specialty Pharmacy
    © 2025 MMIT

    • Angela Maas

    Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

    Back to Radar on Specialty Pharmacy

Related Posts

The Latest
Premium Categories
Meet Our Reporters

Lauren Flynn Kelly

Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

View Lauren Flynn Kelly's Profile

Angela Maas

Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

View Angela Maas's Profile

Leslie Small

Managing Editor, Health Plan Weekly and Radar on Drug Benefits

View Leslie Small's Profile

Tim Casey

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Tim Casey’s Profile

Meet Our Reporters

Lauren Flynn Kelly

Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

View Lauren Flynn Kelly's Profile

Angela Maas

Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

View Angela Maas's Profile

Leslie Small

Managing Editor, Health Plan Weekly and Radar on Drug Benefits

View Leslie Small's Profile

Tim Casey

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Tim Casey’s Profile

Tags
Biosimilars
drug pricing
specialty drugs
market access
drug pricing
×

PREMIUM CONTENT AND PREMIUM INSIGHTS

To gain access to this article you need to have a Premium Subscription.
Click here to access today !